COVID SUPPLEMENTAL

The COVID Supplemental Appropriations Act, 2022 provides roughly $15 billion in emergency funding for the Department of Health and Human Services (HHS) and USAID for therapeutics, vaccines, and diagnostics, as well as for research and clinical trials for emerging coronavirus variants.

**HIGHLIGHTS**

- Provides **$10.6 billion to HHS**, most of which will go to the Biomedical Advanced Research and Development Authority (BARDA) for:
  - Research, development, manufacture, production, purchase, and administration of *therapeutics*; and
  - Research and clinical trials for *emerging coronavirus variants*; and for support in the sustainment and expansion of vaccine manufacturing capacity.

- Ensures transparency of the Administration’s use of these funds, by mandating detailed, updated *spend plans; periodic obligation reports; and notifications* regarding planned uses of the funds, the current inventory of vaccines, therapeutics, and diagnostics; and distribution of vaccines, therapeutics, and diagnostics by state.

- Provides $5 billion to USAID *accelerate international vaccination efforts* and for humanitarian assistance in response to the continued impacts of COVID worldwide.

- **Funding provided to HHS and USAID is offset** through the rescission of previously appropriated funds:
  - $1 billion in ARP funds to the Secretary of Agriculture;
  - $650 million from CARES to the Secretary of Agriculture;
  - $2.95 unobligated PPP funds, stemming from recoveries;
  - $1 billion in unexpended PPP balances;
  - $7 billion in ARP State and Local Coronavirus Relief Funds;
  - $100 million in unobligated ARP Higher Education Emergency Relief Fund; and
  - $2 billion ARP Aviation Manufacturing Jobs Protection Program.